This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Subscribe To Our Newsletter & Stay Updated
